Updated, Subgroup Analyses of BOLERO-2 Confirm Efficacy of Everolimus plus Exemestane in Postmenopausal Women with Advanced Breast Cancer

Share this content:
Updated, Subgroup Analyses of BOLERO-2 Confirm Efficacy of Everolimus plus Exemestane in Postmenopau
Updated, Subgroup Analyses of BOLERO-2 Confirm Efficacy of Everolimus plus Exemestane in Postmenopau

CME

Program Description:

Several analyses of the international randomized phase 3 Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) plus exemestane versus exemestane alone for the treatment of postmenopausal women with HER2-negative, hormone receptor-positive (HR+) advanced breast cancer, including updated efficacy results, health-related quality of life (QOL), effects in Asian populations, and safety in women over 65 years of age, were explored in presentations at the 2012 Annual Meeting of the American Society of Clinical Oncology.

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

Recognize hyperactivation of the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway in endocrine-resistant breast cancer cells.

Assess the efficacy of the mTOR inhibitor everolimus in combination with the steroidal aromatase inhibitor exemestane in patients with HR+ advanced breast cancer.

Click Next to begin the activity.

Page 1 of 7

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs